MX2024001242A - Una composicion farmaceutica para la obtencion de imagenes. - Google Patents

Una composicion farmaceutica para la obtencion de imagenes.

Info

Publication number
MX2024001242A
MX2024001242A MX2024001242A MX2024001242A MX2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A MX 2024001242 A MX2024001242 A MX 2024001242A
Authority
MX
Mexico
Prior art keywords
pudexacianinium
intraoperative
ureter
nirf
nirf imaging
Prior art date
Application number
MX2024001242A
Other languages
English (en)
Spanish (es)
Inventor
Masako Saito
Kanji Komatsu
Shin Takusagawa
Herrera Leticia Delgado
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2024001242A publication Critical patent/MX2024001242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024001242A 2021-07-28 2022-07-27 Una composicion farmaceutica para la obtencion de imagenes. MX2024001242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226534P 2021-07-28 2021-07-28
PCT/IB2022/056957 WO2023007404A1 (en) 2021-07-28 2022-07-27 Pudexacianinium for nirf imaging

Publications (1)

Publication Number Publication Date
MX2024001242A true MX2024001242A (es) 2024-02-13

Family

ID=82898903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001242A MX2024001242A (es) 2021-07-28 2022-07-27 Una composicion farmaceutica para la obtencion de imagenes.

Country Status (9)

Country Link
US (1) US20240342316A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376896A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527715A (cg-RX-API-DMAC7.html)
KR (1) KR20240041952A (cg-RX-API-DMAC7.html)
CN (1) CN117715661A (cg-RX-API-DMAC7.html)
AU (1) AU2022321011A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226034A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001242A (cg-RX-API-DMAC7.html)
WO (1) WO2023007404A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024084287A1 (en) * 2022-10-21 2024-04-25 Astellas Pharma Inc. Composition for near infrared lymphatic imaging and uses and dosages therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056131B2 (en) 2010-01-28 2015-06-16 National University Corporation Mie University Indocyanine compound, synthesis method and purification method thereof, diagnostic composition using the indocyanine compound, and device for measuring biokinetics and device for visualizing circulation using the diagnostic composition

Also Published As

Publication number Publication date
KR20240041952A (ko) 2024-04-01
EP4376896A1 (en) 2024-06-05
AU2022321011A1 (en) 2024-01-25
WO2023007404A1 (en) 2023-02-02
CN117715661A (zh) 2024-03-15
CA3226034A1 (en) 2023-02-02
JP2024527715A (ja) 2024-07-26
US20240342316A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
ES2705016T3 (es) Derivado de rapamicina para el tratamiento de cáncer de pulmón
JP5911929B2 (ja) 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬
JP2021516262A (ja) リツキシマブ及び/若しくはベンダムスチンと組み合わされたBcl−2阻害剤又はCHOPと組み合わされたBcl−2阻害剤の相乗的な抗腫瘍効果
AU2009215329B2 (en) Combination comprising paclitaxel for treating ovarian cancer
RU2375058C2 (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
Qi et al. Intrathecal dexmedetomidine as adjuvant to ropivacaine in hysteroscopic surgery: a prospective, randomized control study
US10617667B2 (en) Method for treating brain tumors
KR20100038061A (ko) 리마프로스트를 함유하는, 암화학 요법에 기인하는 말초신경장애 예방, 치료 및/또는 증상 경감제
JP2020502182A5 (cg-RX-API-DMAC7.html)
US20120295871A1 (en) Heparin-based compositions and methods for the inhibition of metastasis
Hollebecque et al. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients
ES3015427T3 (en) Use of non-peptide nk1 antagonists in a predetermined dose for the treatment of cancer
Malik et al. Combined Psoas Compartment and Sciatic Nerve Block for Lower Limb Surgery: An Alternative Anesthetic Option in High‑risk Geriatric Patients
Ikegaki et al. Delirium prolonged for three days after addition of one dose of 5 mg methadone to ongoing opioid
Malik Standardization of propofol and ketamine for constant rate infusion and their comparative evaluation with halothane anaesthesia in buffaloes
ECSP12012350A (es) Formulación de liberación sostenida
Yang et al. Pleural effusion and atelectasis during continuous interscalene brachial plexus block-A case report
Lee et al. Total intravenous anesthesia using remimazolam for patients with heart failure with reduced ejection fraction: a case series
Vandepitte et al. “Don't Throw the Baby Out With the Bath Water:” A Reply to Dr. Onwochei et al
US20150045391A1 (en) Filanesib combined with pomalidomide displays enhanced anti-tumor activity
Kaushik et al. A Comparative Analysis on Anesthetic Requirement and Peri-Operative Hemodynamic Stress Response after a Single Dose of Dexmedetomidine and Fentanyl: A Hospital Based Study
RU2549474C1 (ru) Способ премедикации перед оперативными гинекологическими вмешательствами, выполняемыми в условиях общей анестезии
Tsygankov et al. Comparison of hemodynamic parameters in patients during transcuretral resection of the urinary bubble during spinal anesthesia using levobupivakaina and popivacaine
Kim et al. The dose effect of ephedrine on the onset time and intubating conditions after cisatracurium administration: 9AP4-2
WO2006062072A1 (ja) 転移癌治療剤および癌転移抑制剤